Abstract 214P
Background
Epithelial-Mesenchymal Transition (EMT) is a dynamic process hypothesized to occur in carcinoma during invasion and metastasis. Tyrosine Kinase Inhibitor Sunitinib stands as the main first-line treatment in metastatic renal clear cell carcinoma (mRCC). Activation of IGF and TGFβpathways are known to be associated with the acquisition of EMT and chemoresistance in cancer cells. Downregulation of EMT regulators is a promising therapeutic strategy to overcome resistance or resensitize RCC to Sunitinib therapy. Furthermore, indirect and specific inhibition of IGF axis by inhibition of PAPP-A, which regulates IGF signaling, represents a novel approach in mRCC treatment.
Methods
RCC tumor tissues, primary and metastatic RCC cell lines (parental and Sunitinib resistant) were examined for EMT proteins (Ecad & Ncad), EMT regulators, TGFβ and IGF/PAPP-A axis by qRT-PCR and western blot. Analysis of TCGA transcriptome profiling dataset was performed.
Results
Higher expression of N cadherin and low expression of E cadherin indicating mesenchymal signature was noted in RCC patient tumors associated with significantly upregulated expression of known EMT inducers; TGFβ and IGF1R as compared to non-tumor adjacent kidney tissues. Expression of IGF1 axis components, EMT markers and TGFβ was confirmed via qRT-PCR in primary and metastatic RCC cell lines. Sunitinib-induced EMT was confirmed by upregulation of N cad and downregulation of Ecad in 786-O RCC cell line. Analysis of TCGA dataset revealed that IGF1R expression (n = 792, HR 1.45, p = 0.01) and TGFβ expression (n = 792, HR 2.14, p < 0.01) resulted in worse overall survival in mRCC patients, a non-significant trend towards worse survival was noted with PAPP-A expression (n = 792, HR 1.27, p = 0.1).
Conclusions
Our data suggest that EMT may play a role in RCC progression and may be a mechanism of drug resistance to Sunitinib. TGFβ and IGF pathways are dysregulated in RCC, therefore direct or indirect targeting of these pathways may prove to be a novel strategy to delay resistance to Sunitinib or resensitize RCC to VEGF inhibitor therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fiona Elsey Cancer Research Institute.
Funding
Fiona Elsey Cancer Research Institute.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
51P - Enhancing the anti-breast tumour activity of STING through a novel sting transcriptional regulator
Presenter: Hanchu Xiong
Session: Poster display session
Resources:
Abstract
52P - Reverse Warburg effect-related mitochondrial activity and 18F-FDG uptake in invasive ductal carcinoma
Presenter: Byung Wook Choi
Session: Poster display session
Resources:
Abstract
53P - Phase II study of atorvastatin in combination with radiotherapy and temozolomide in patients with glioblastoma (ART): Final analysis report
Presenter: Abdullah Altwairgi
Session: Poster display session
Resources:
Abstract
54P - Association between Parkinson’s disease and brain tumours: A nationwide population-based cohort study
Presenter: Joo-hyun Park
Session: Poster display session
Resources:
Abstract
55P - Toxicity profiles of treatment with modern fractionated radiotherapy, contemporary stereotactic radiosurgery, or transsphenoidal surgery in non-functioning pituitary macroadenoma
Presenter: Kevin Sheng-Po Yuan
Session: Poster display session
Resources:
Abstract
56P - Hippocampal avoidance in WBRT for metastases: Comparative neurocognitive and dosimetric assessment
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
57P - Multidisciplinary brain metastasis clinic: Is it effective and worthwhile?
Presenter: Annu Rajpurohit
Session: Poster display session
Resources:
Abstract
58P - Functional status as a determinant prognostic factor for overall survival in adult patients with medulloblastoma treated with chemotherapy and radiotherapy
Presenter: Juan Ayala Alvarez
Session: Poster display session
Resources:
Abstract
59P - Pattern of care in high-grade gliomas after recurrence
Presenter: Nandini Menon
Session: Poster display session
Resources:
Abstract
60P - Five fractions plus “SRS” boost combined with temozolamide for newly diagnosed and recurrent glioblastoma multiforme (GBM)
Presenter: Azhar Rashid
Session: Poster display session
Resources:
Abstract